0.1594
6.34%
+0.0095
After Hours:
.1594
Tonix Pharmaceuticals Holding Corp stock is currently priced at $0.1594, with a 24-hour trading volume of 2.01M.
It has seen a +6.34% increased in the last 24 hours and a -50.34% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.14 pivot point. If it approaches the $0.1599 resistance level, significant changes may occur.
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Tonix Pharmaceuticals Holding Corp (TNXP) Net Income 2024
TNXP net income (TTM) was -$121.02 million for the quarter ending September 30, 2023, a -11.96% decrease year-over-year.
Tonix Pharmaceuticals Holding Corp (TNXP) Cash Flow 2024
TNXP recorded a free cash flow (TTM) of -$114.09 million for the quarter ending September 30, 2023, a +31.80% increase year-over-year.
Tonix Pharmaceuticals Holding Corp (TNXP) Earnings per Share 2024
TNXP earnings per share (TTM) was -$11.26 for the quarter ending September 30, 2023, a +68.67% growth year-over-year.
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
GlobeNewswire Inc.
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
GlobeNewswire Inc.
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
GlobeNewswire Inc.
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
GlobeNewswire Inc.
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy
GlobeNewswire Inc.
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Cap:
|
Volume (24h):